Open label randomized phase III study of weekly docetaxel and docetaxel every 3 weeks in patients with metastatic breast cancer, resistant to prior chemotherapy.

Trial Profile

Open label randomized phase III study of weekly docetaxel and docetaxel every 3 weeks in patients with metastatic breast cancer, resistant to prior chemotherapy.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2011

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms TAX-613
  • Most Recent Events

    • 12 Oct 2009 New source identified and integrated (Netherlands Trial Register) (NTR1944).
    • 23 Aug 2009 Planned initiation date changed from 1 Feb 2001 to 18 Jul 2000 as reported by Netherlands Trial Register.
    • 23 Aug 2009 Planned end date changed from 1 Apr 2006 to 1 Jan 2008 as reported by Netherlands Trial Register.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top